Key result
CV, HF, or renal hospitalizations in T2D linked to higher healthcare utilization and total costs.
Why the study?
Comorbidity-related hospitalizations can significantly impact longitudinal care in patients with T2D, but the incremental all-cause HCRU and costs associated with CV-, HF-, or renal-related hospitalizations needed estimation.
Does cardiovascular, heart failure, or renal-related hospitalization increase health care resource utilization and costs in patients with type 2 diabetes?
Cohort (n=409,460)
Does cardiovascular, heart failure, or renal-related hospitalization increase health care resource utilization and costs in patients with type 2 diabetes?
In patients with type 2 diabetes, cardiovascular, heart failure, and renal hospitalizations are associated with significantly increased subsequent healthcare resource utilization and costs.
May drive higher subsequent costs after CV/HF/renal hospitalization in type 2 diabetes; leaves open whether prevention reduces utilization.
OBJECTIVES: In patients with type 2 diabetes (T2D), comorbidity-related hospitalizations can have significant impact on longitudinal care. This study aimed to estimate incremental all-cause health care resource utilization (HCRU) and costs between patients with T2D who experienced cardiovascular (CV)-, heart failure (HF)-, or renal-related hospitalizations vs those who did not. STUDY DESIGN: This was a retrospective cohort study using data from a large national health plan. METHODS: Patients with T2D aged 18 to 90 years with CV, HF, or renal hospitalizations were identified from the Humana claims database from October 1, 2009, to September 30, 2015, and separated into CV, HF, and renal cohorts. Patients had 12 months of continuous enrollment prior to the date of first hospitalization (index) and were followed for up to 12 months. Per-patient per-month (PPPM) all-cause HCRU and costs for hospitalized patients were compared with those of no-CV, no-HF, and no-renal cohorts. Differences in baseline characteristics between cohorts were controlled for using generalized linear models. RESULTS: A total of 221,229, 68,126, and 120,105 patients were included in the CV, HF, and renal cohorts, respectively; these patients were older and had higher Deyo-Charlson Comorbidity Index scores than patients in the no-CV, no-HF, and no-renal cohorts. Adjusted for baseline covariates, they had higher mean PPPM inpatient stays, outpatient visits, emergency department visits, and total health care costs. CONCLUSIONS: Among patients with T2D, concurrent CV, HF, or renal events present significant disease burden leading to poor quality of life. This information can be used to guide disease management strategies and interventions aimed at reducing comorbidity-related hospitalizations and health care costs, thus providing improved quality of life for these patients.
No takes yet. Share an insight, caveat, or question.
A 2020 study conducted a cohort in Type 2 diabetes (n=409,460). Cardiovascular, heart failure, or renal-related hospitalizations vs. Patients with T2D without cardiovascular, heart failure, or renal-related hospitalizations was evaluated on Per-patient per-month (PPPM) all-cause health care resource utilization (HCRU) and costs. In patients with type 2 diabetes, cardiovascular, heart failure, or renal hospitalizations were associated with higher mean per-patient per-month healthcare resource utilization and total costs.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: